ReviewESMO gastrointestinal oncology2026
Innovative radiotherapy approaches.
Review in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A systematic review of heterogeneity in clinical trial design for anal cancer radiotherapy-immunotherapy combinations.Clinical and translational radiation oncology · 2026Review
- Rewriting the future of anal cancer care: From disparities to data-driven decisions.ESMO gastrointestinal oncology · 2026Article
- Revisiting Radiotherapy for Hidradenitis Suppurativa: Clinical Outcomes, Safety, and Optimization Strategies: A Systematic Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) with concurrent chemotherapy is the standard of care for squamous-cell carcinoma of the anal canal (SCCAC), achieving favorable results in terms of local control and overall survival. However, locoregional failure remains common despite advances such as intensity-modulated radiotherapy (IMRT), which reduces toxicity but has limitations. Despite the benefits of IMRT, frequent and severe toxicities persist, affecting patients' quality of life. This review examines strategies to improve RT outcomes in anal cancer. These include risk-adapted target delineation, daily target volume adjustment, brachytherapy, magnetic resonance-guided linear accelerator for radiation therapy (MRI-Linac), and proton therapy. Risk-adapted delineation proposes personalized treatment volumes based on individual risk factors, potentially improving efficacy and safety. With image-guided implantation and intensity-modulated dose delivery, interventional RT (brachytherapy), including modern brachytherapy, offers advantages in dose escalation while minimizing toxicity. Proton therapy, which delivers energy at specific depths, shows promise in reducing toxicity, although further prospective studies are needed. Advanced RT delivery modalities, such as online adaptive RT and MRI-Linac, offer opportunities to improve treatment outcomes by accounting for daily anatomical variations and allowing personalized dose adjustments. The aim of the integration of these technologies is to achieve optimal therapeutic ratios, minimize toxicities, and improve patient outcomes in the treatment of anal cancer. To address the remaining challenges and optimize RT approaches for SCCAC, ongoing trials are investigating dose-volume stratification, adaptive treatment, and proton therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.